Single NX-1207 Dose Significantly Improved BPH Symptom Scores And Significantly Reduced Prostate Size After 90 Days

Main Category: Prostate / Prostate Cancer
Also Included In: Urology / Nephrology;  Clinical Trials / Drug Trials
Article Date: 13 Oct 2008 - 3:00 PDT

email to a friend   printer friendly   opinions  

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is please to announce that the presentation of NX-1207 clinical study data at the AUA South Central Section annual meeting in Santa Ana Pueblo, NM was featured in the Urology Times, the widely distributed and most read publication of U.S. urologists. At the meeting, Raphael Wurzel, MD, reviewed clinical data from the most recent NX-1207 trial that showed that treatment with a single dose of NX-1207 significantly improved BPH symptom scores and significantly reduced prostate size after 90 days.

In addition, news of the NX-1207 clinical studies success has been shown on several U.S. television networks.

Dr. Wurzel's presentation was one of series of recent presentations of NX-1207 clinical study data at annual regional meetings of urologists across the U.S. Further presentations are scheduled in the coming month. NX-1207 has entered its Phase 3 development program, the last stage before filing with the FDA for approval for commercial distribution and sale. The drug involves a new targeted approach to the treatment of BPH. NX-1207 is injected by a urologist in an office setting directly into the zone of the prostate where the enlargement occurs and the injection takes only a few minutes and involves little or no pain or discomfort. In multicenter U.S. clinical trials to date NX-1207 has been found to produce improvements in BPH symptom score that are approximately double that reported for currently approved BPH drugs without the side effects associated with those drugs, which can include sexual dysfunction, blood pressure changes and other adverse reactions.

Presentations of clinical study data at urology have been well-received and the Company has received a large number of communications from patients and doctors throughout the U.S. and internationally, interested in participating in clinical trials and wanting to learn more about the drug. Investigative site recruitment activities are proceeding well.

http://www.nymox.com

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The conduct of clinical trials and the development of drug products involve substantial risks and uncertainties and actual results may differ materially from expectations. Promising early results do not ensure that later stage or larger scale clinical trials will be successful or will proceed as expected. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

• Additional
• References
• Citations